Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Piperaquine · 1 trial · 1 indication
Maximum observed drug concentration in observed individual concentration-time profile.
Ratio between parasitemia at the onset of drug treatment and 48 hours later. The PRR is defined as the ratio of the number of parasites at time of treatment divided by the number after a given amount of time has elapsed post-treatment. This time period is normally 48 hours as this is the time taken for P. falciparum parasites to pass through their asexual erythrocytic life cycle.
PCt1/2 = Parasite Clearance Half-life;
| Arm | Type | Description |
|---|---|---|
| Cohort 1: Treatment Group A: 200mg of OZ439 and 480 mg PQP | EXPERIMENTAL | 200mg of OZ439 and 480 mg PQP. (OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension) and PQP. |
| Cohort 1:Treatment Group B: 200mg of OZ439 and 640 mg PQP | EXPERIMENTAL | 200mg of OZ439 and 640 mg PQP. (OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension) and PQP. |
| Cohort 1:Treatment Group C: 400mg of OZ439 and 480 mg PQP | EXPERIMENTAL | 400mg of OZ439 and 480 mg PQP. (OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension) and PQP. |
| Cohort 1Treatment Group D and Cohort 3 Treatment group A : 400mg of OZ439 and 640 mg PQP | EXPERIMENTAL | 400mg of OZ439 and 640 mg PQP. (OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension) and PQP. |
| Cohort 2: Treatment Group A: 800mg of OZ439 and 960 mg PQP | EXPERIMENTAL | 800mg of OZ439 and 960 mg PQP. |
| Cohort 2: Treatment Group B: 200mg of OZ439 and 320 mg PQP | EXPERIMENTAL | 200mg of OZ439 and 320 mg PQP. |
| Cohort 3: Treatment Group B: 800mg of OZ439 and 640 mg PQP | EXPERIMENTAL | 800mg of OZ439 and 640 mg PQP |
| Name | Type | Description |
|---|---|---|
| 480 mg Piperaquine phosphate | DRUG | 480 mg Piperaquine is a bis 4-aminoquinoline and was used mainly in China from the 1960's to the 1980's as an antimalarial monotherapy. |
| 640 mg Piperaquine phosphate | DRUG | 640 mg Piperaquine is a bis 4-aminoquinoline and was used mainly in China from the 1960's to the 1980's as an antimalarial monotherapy. |
| 200 mg OZ 439 | DRUG | 200 mg OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension |
| 400 mg OZ 439 | DRUG | 400 mg OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension |
| 800 mg OZ 439 | DRUG | 800 mg OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension |
| 960 mg PQP | DRUG | 960 mg Piperaquine is a bis 4-aminoquinoline and was used mainly in China from the 1960's to the 1980's as an antimalarial monotherapy. |
| 320 mg PQP | DRUG | 320 mg Piperaquine is a bis 4-aminoquinoline and was used mainly in China from the 1960's to the 1980's as an antimalarial monotherapy. |
Inclusion Criteria: 1. Adult (male and female) subjects between 18 and 55 years of age inclusive, who do not live alone (from inoculation day until at least the end of the Riamet® treatment) and will be contactable and available for the duration of the trial and contactable up to 2 weeks following ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 3 | PHASE3 | Tafenoquine, Primaquine, Chloroquine |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE2 | INE963, KAE609, KLU156 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
Piperaquine is an investigational small molecule being developed for the treatment of malaria. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied for its safety, tolerability, and antimalarial activity in clinical trials.
Piperaquine is being developed by CNS Pharmaceuticals, Inc., a company traded on the NASDAQ under the ticker symbol CNSP. The company is conducting clinical research on this small molecule for the treatment of malaria.
Piperaquine is in Phase 1 clinical development. It is an investigational drug and has not yet been approved for commercial use. The Phase 1 trial has been completed, and the drug remains in early-stage clinical development for malaria.
Piperaquine has been studied in one completed Phase 1 clinical trial, identified as NCT03542149. This trial evaluated the safety, tolerability, and antimalarial activity of single doses of OZ439 and Piperaquine in healthy volunteers in Australia. The trial enrolled 24 participants.
No, Piperaquine and OZ439 are distinct compounds. They were studied together in a clinical trial (NCT03542149) that evaluated the safety, tolerability, and antimalarial activity of single doses of both drugs. Piperaquine is being developed by CNS Pharmaceuticals, Inc.